Health · 5 views
Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression
(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major…
Summary
(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major depressive
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Financial incentives nearly double quit rates among underserved people who smoke in national studyContinue reading
- Lowering blood pressure after stroke or with diabetes poses challenges, in research and practiceContinue reading
- Potential driver of severe early-onset preeclampsia identifiedContinue reading
- Avoiding Chemo in Breast Cancer; Psychedelic Medication for DepressionContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow